The company has devoted a certain amount of revenue each year to continuing the fight against cancer by developing new detection tools.
“Nuclepore – another ’64 polymer advance – is now in production at Pleasanton, Calif., supplying medical and other customers with a filter whose extremely fine pores can be used in such ways as isolating cancer cells for medical research.”
For almost half a century GE has been on the front lines of cancer research. The company’s scientists and researchers have been central to the development and improvement of cancer screening tools that have detected cancer before it kills.
From the company’s earliest investment in x-ray machines, GE’s cancer screening tools are part of what is now a healthcare innovator that employs over 46,000 people worldwide and have saved countless more lives.
A decade after the company started production of Nuclepore in its northern California plant, GE joined the fight against cancer at a prescient time. By 1974, cancer was no longer talked about behind closed doors in hushed tones. That year First Lady Betty Ford was treated for breast cancer just weeks after her husband, Gerald Ford, became President after Richard Nixon’s resignation. Her battle against the disease inspired women to become more vigilant about screening themselves for the disease. Meanwhile, GE introduced the MMX II, a new mammographic x-ray system. Other instruments, including the Spectratherm thermographic system and Maxiscan body scanner, led the way in the early detection of cancerous tumors. 200,000 Americans, or one in three stricken with cancer, survived in 1974 because of improved screening procedures and increased awareness about detecting cancer at its earliest stages.
Originally published on Triple Pundit, republished with kind permission.